– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study –– ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity –– MEI to Continue
– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –– Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II